A single infusion of the experimental CRISPR-Cas9 therapy CTX310 kept LDL cholesterol down 52.5% and triglycerides down 47.8% a year later in a first-in-human trial, with no serious treatment-related adverse events.
An experimental pill called enlicitide slashed levels of low-density lipoprotein (LDL) cholesterol, commonly known as “bad” cholesterol, by up to 60%, a new phase three clinical trial published in The New England Journal of Medicine showed. If approved by the Food and Drug... Continue Reading →